New data from the CTX stem cell platform will be presented today supporting the potential to re-programme CTX stem cells to generate new allogeneic cell lines with potential utility as therapeutic candidates. Whilst early, this data is encouraging, adding support for the company’s proprietary immortalisation technology and suggesting a wider utility of the CTX line as a source of ‘off the shelf’ allogeneic stem cells. ReNeuron will continue to explore these new allogeneic cell lines as potential ....
23 Oct 2019
New CTX stem cell platform data suggests expanded utility
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
New CTX stem cell platform data suggests expanded utility
ReNeuron Group plc (RENE:LON) | 3.0 0 0.0% | Mkt Cap: 1.74m
- Published:
23 Oct 2019 -
Author:
Jens Lindqvist -
Pages:
3
New data from the CTX stem cell platform will be presented today supporting the potential to re-programme CTX stem cells to generate new allogeneic cell lines with potential utility as therapeutic candidates. Whilst early, this data is encouraging, adding support for the company’s proprietary immortalisation technology and suggesting a wider utility of the CTX line as a source of ‘off the shelf’ allogeneic stem cells. ReNeuron will continue to explore these new allogeneic cell lines as potential ....